P

fizer’s $68 billion merger with Wyeth should be completed later today now that the deal has been given the thumbs-up from antitrust regulators in the USA and Canada.

The US Federal Trade Commission and the Canadian Competition Bureau have approved the acquisition, now that Pfizer and Wyeth have agreed to sell parts of their animal health business to Boehringer Ingelheim, including vaccine lines and a wide range of pharmaceuticals for pets, cattle and other species. The Canada green light also requires Pfizer to amend an existing distribution agreement with Paladin Labs in the country related to Estring (estradiol) vaginal ring.

The FTC said that “after a thorough investigation”, it had concluded that the transaction “does not raise anticompetitive concerns in any human health product markets”. This latest approval comes a couple of weeks after China and Australia backed the link-up, while the European Commission granted regulatory approval for the transaction in July.

Patent dispute with Mylan over Vfend settled
Meantime, Pfizer has reached agreement with Mylan with regards to a generic version of the New York-based behemoth’s antifungal Vfend (voriconazole) tablets.

Under the terms of the settlement, the details of which were not disclosed, Mylan can start marketing its pill in the USA from the first quarter of 2011. The deal is subject to review by the US Department of Justice and the FTC.

Mylan had previously notified Pfizer that it had filed an Abbreviated New Drug Application with the US Food and Drug Administration, challenging four patents relating to voriconazole, which expire between 2009 and 2016. However Pfizer notes that this latest agreement does not cover Vfend products for intravenous use or oral suspension.

Mylan, which believes it will be eligible for 180 days of marketing exclusivity as a result of being the first to file an ANDA, said that US sales of Vfend reached $164 million for the year ended June 30.